People · Operator

Mark J. Brister

Named in public records as an officer, director or promoter · active 2018–2018 · Biotechnology

1
Companies
1
Filings
$48.9M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Obalon Therapeutics IncBiotechnologySeries B$48.9M$396.9M2018
Operator network

Mark J. Brister at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Kim Puloma Kamdar · 2 companies · 1 sharedKim Puloma KamdarAndrew Rasdal · 1 companies · 1 sharedAndrew RasdalDavid J. Moatazedi · 1 companies · 1 sharedDavid J. MoatazediDouglas C. Puloma Sampson · 1 companies · 1 sharedDouglas C. Puloma…Douglas J. Fisher · 1 companies · 1 sharedDouglas J. FisherDoug Puloma Fisher · 1 companies · 1 sharedDoug Puloma FisherKelly J. Huang, Ph.D. · 1 companies · 1 sharedKelly J. Huang, P…Kim J. Kamdar, Ph.D. · 1 companies · 1 sharedKim J. Kamdar, Ph…Les J. Howe · 1 companies · 1 sharedLes J. HoweRaymond J. Dittamore · 1 companies · 1 sharedRaymond J. Dittam…Sharon J. Stevenson, DVM Ph.D. · 1 companies · 1 sharedSharon J. Stevens…Sharon Puloma Stevenson · 1 companies · 1 sharedSharon Puloma Ste…William J. Plovanic · 1 companies · 1 sharedWilliam J. Plovan…Obalon Therapeutics Inc · $48.9M raisedObalon Therapeutics I…Mark J. BristerMB
Mark J. Brister Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Mark J. Brister on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Kim Puloma Kamdar12
Andrew Rasdal11
Douglas C. Puloma Sampson11
Sharon Puloma Stevenson11
Doug Puloma Fisher11
Les J. Howe11
Kelly J. Huang, Ph.D.11
Douglas J. Fisher11
David J. Moatazedi11
Raymond J. Dittamore11
Sharon J. Stevenson, DVM Ph.D.11
Kim J. Kamdar, Ph.D.11
William J. Plovanic11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.